In a study on mares and foals,(1) Meriva® was able to down-regulate the expression of a series of cytokines, enzymes and transcription factors involved in the natural inflammation response. Meriva® was administered for 15 days, and gene expression was compared with the initial state at days 4, 8 and 15 from the beginning of the treatment.
In mares, curcumin inhibited the expression of COX-2, TNF-?, IL-1?, IL-1RN and IL-6, with special significance being observed for IL-1? and IL-6. In foals, curcumin significantly inhibited the expression of COX-2, TNF-?, IL-1?, IL1RN and IL-6.
In a recent genomic study(2) on dogs, the differential modulation of inflammation response markers by Meriva® and another agent was investigated. Meriva® (40 mg/Kg/day, corresponding to 8 mg/Kg/day of curcumin) or another agent (4 mg/Kg/day) were administered to two groups of 6 JC dogs for 20 days. Gene expression was compared with a control group of 6 dogs at the beginning (T0) and at the end of the study (T20).
At the beginning of the study, the two experimental groups of dogs showed the differential expression of 475 (other agent arm) and 498 (Meriva® arm) genes compared to the control group.
These genes could be broadly defined as pro-inflammatory response markers. Both curcumin and the other agent could significantly attenuate the expression of this genomic signature, since at the end of the study only 173- (other agent arm) and 141 (Meriva® arm) genes were deferentially expressed compared to the control group.
From a genomic standpoint, Meriva® outperformed the other agent, since important genes underlying the production of i?B and IL18 were modulated only by Meriva®. Compared to the other agent, Meriva® could down-regulate the inflammatory response pathway mediated by TNF?, macrophage proliferation and fibrinolysis.
Taken together, these provide a genomic rationale for the use of Meriva® for the complementary support of joint health, an indication validated by human clinical studies. A recent registry study(3) on 61 subjects evaluated Meriva® efficacy in supporting healthy prostate function compared to the best standard management (BSM) available.
Signs and symptoms were evaluated using the International Prostate Symptom Score (IPSS). A first group of 33 subjects were administered with BSM in association with Meriva® at the dosage of 500 mg/day for at least 24 weeks, while the remaining 28 volunteers (control group) were administered with only BSM. All IPSS scores and quality of life improved in both groups, while in the Meriva® arm were significantly better than in the BSM-only group (p<0.05 for IPSS and p<0.01 for quality of life). All these results underline the nutritional potential of curcumin as a natural ingredient to support the body’s inflammation response function.
(1) Farinacci M., Gaspardo B., Colitti M., Stefanon B., Ital. J. Anim.Sci, 2009. 8(2): p. 84-86.
(2) Colitti M., Gaspardo B., Della Pria A., Scaini C., Stefanon B., Vet Imm and Immunopat 147 2012: p136-46
(3) Ledda A., Belcaro G., Dugall M., Luzzi R., Scoccianti M., Togni S., Appendino G., Ciammaichella G., Panminerva Med. 2012 54(Suppl. 1 to No. 4): 17-22